Welcome to our dedicated page for Aardvark Therapeutics SEC filings (Ticker: AARD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aardvark Therapeutics, Inc. (Nasdaq: AARD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Aardvark uses forms such as Form 8-K to report material events, clinical and scientific updates, and quarterly financial results related to its pipeline of small-molecule therapies for Prader-Willi Syndrome and metabolic diseases.
Recent AARD filings include Form 8-K reports furnishing quarterly financial results and business updates, such as results for periods ended June 30 and September 30, along with commentary on research and development spending, general and administrative expenses, and cash, cash equivalents, and short-term investments. These filings often incorporate press releases as exhibits, giving investors a consolidated view of the company’s financial condition and development plans.
Aardvark also files 8-Ks under Items 7.01 and 8.01 to describe clinical and scientific milestones, including presentations at ObesityWeek, new preclinical data on ARD-201 and WE-868, and alignment with the U.S. Food and Drug Administration on protocol amendments to the Phase 3 HERO trial of ARD-101 in Prader-Willi Syndrome. Other 8-Ks document investor webinars reviewing ARD-101 and ARD-201 programs and provide access to slide presentations used in those events.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on topics such as clinical trial progress, regulatory interactions, financial trends, and risk factor references. Users can monitor new 8-Ks and, when available, 10-Q and 10-K reports to follow how Aardvark describes its pipeline, capital resources, and development risks over time.
For those researching AARD stock, this filings page offers a structured way to review the company’s official disclosures, including material events, scientific data announcements, and financial reporting, with tools that make complex SEC documents easier to interpret.
Aardvark Therapeutics, Inc. furnished a Form 8-K to announce a press release with financial results for the third quarter ended September 30, 2025, along with pipeline and business updates. The press release is provided as Exhibit 99.1, dated November 13, 2025.
The company states the information in Item 2.02 (including Exhibit 99.1) is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference except as specifically noted. The filing also includes the Cover Page Interactive Data File as Exhibit 104. Aardvark’s common stock (AARD) is listed on The Nasdaq Stock Market LLC.
Aardvark Therapeutics filed an 8-K announcing it hosted an investor webinar on November 5, 2025 to review its ARD-101 and ARD-201 programs and its ObesityWeek 2025 presentations. The slide deck used is posted on the company’s website and is filed as Exhibit 99.1. The presentation is current as of November 5, 2025, and the company disclaims any obligation to update the material.
Aardvark Therapeutics (AARD) furnished an update under Regulation FD about new scientific disclosures at ObesityWeek 2025. The company presented two posters: “TAS2R Agonist ARD-101 Attenuates Weight Gain in Mice and Reduces Hunger in Adults with Obesity” and “An Isoflavonoid Modulator of Oxidative Metabolism with Therapeutic Potential in Obesity and Diabetes.” It also announced an investor webinar on November 5, 2025 covering ARD-101, ARD-201, and the conference data.
The materials are provided as Exhibits 99.1, 99.2, and 99.3 and are furnished, not filed, under the Exchange Act.
Aardvark Therapeutics (AARD) reported an insider option exercise by its Chief Operating Officer. On 10/15/2025, the officer exercised stock options (code M) to acquire 1,250 shares of common stock at an exercise price of $4.24 per share, held directly. Following the transaction, 40,052 derivative securities (stock options) remained beneficially owned.
The option carries an expiration date of 07/20/2034. Per the footnote, 1/48th vested on 07/27/2024 and continues vesting in equal monthly installments, subject to continuous service.
Aardvark Therapeutics (AARD) reported an insider transaction. On 10/15/2025, the CEO, who is also a Director and 10% Owner, exercised 1,229 stock options (transaction code M) at $4.24 and acquired 1,229 common shares.
Following the transaction, beneficial ownership was 1,544,613 shares held directly and 1,474,028 shares held indirectly by spouse. The option award shows 40,566 derivative securities beneficially owned after the event, with an expiration date of 07/20/2034.
The filing notes a vesting schedule: 1/48th of the original option vested on 07/27/2024, with 1/48th vesting monthly thereafter, subject to continuous service.
Aardvark Therapeutics, Inc. reported that it has reached alignment with the U.S. Food and Drug Administration on a protocol amendment to its Phase 3 HERO trial of ARD-101 for treating hyperphagia associated with Prader-Willi Syndrome.
The amendment lowers the minimum age for trial eligibility from 13 to 10 years old, allowing younger patients with this condition to participate in the Phase 3 study. The company announced this change in a press release dated October 8, 2025, which is included as an exhibit to the report.
Aardvark Therapeutics CEO and director Tien-Li Lee reported open-market purchases of Aardvark (AARD) common stock on 09/15/2025. The Form 4 shows two purchase transactions: 6,500 shares at a weighted-average price of $9.5106 and 3,500 shares at a weighted-average price of $9.9442. Following these transactions, the reporting person beneficially owned 1,543,384 shares directly and a further 1,474,028 shares indirectly through a spouse. The filing lists no derivative transactions. Footnotes disclose that each reported price is a weighted average from multiple trades within the stated price ranges.
Aardvark Therapeutics (AARD) filed a Form 144 to notify a proposed sale of 10,360 common shares by an affiliate through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $93,413.01 and an approximate sale date of 09/15/2025. The filing shows these shares were acquired from the issuer in a private transaction on 05/16/2019 for cash. The company reports 21,696,893 shares outstanding, which provides context for the size of the proposed sale relative to the float.
The filing also discloses recent sales by VICKERS VENT GLB DEEP-TECH FND I LP of 20,000 shares on 09/02/2025 for gross proceeds of $170,118.00 and 27,691 shares on 08/28/2025 for gross proceeds of $241,565.21. The notice includes the standard signer representation that no undisclosed material adverse information is known to the seller.
Nelson Sun, Chief Financial Officer of Aardvark Therapeutics (AARD), reported an insider purchase of 6,000 shares of the company's common stock at a weighted average price of $8.0733 per share, increasing his beneficial ownership to 105,484 shares.
The filing notes the reported price is a weighted average from multiple trades executed between $8.00 and $8.20 per share, and the reporting person offers to provide details on the per-trade breakdown upon request. This Form 4 documents a direct acquisition by an executive, indicating a personal purchase rather than a derivative transaction.
Form 144 notice for Aardvark Therapeutics, Inc. (AARD) reports a proposed sale of 20,000 common shares through Morgan Stanley Smith Barney valued at $170,118, with an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired from the issuer on 05/16/2019 in a private acquisition and were paid in cash. The filer also disclosed a sale of 27,691 common shares on 08/28/2025 generating $241,565.21 in gross proceeds. The filer affirms no undisclosed material adverse information.